Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eye chart

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    140 result(s) found for: Eye chart. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2010-023216-14 Sponsor Protocol Number: HP-AM2-001 Start Date*: 2011-03-15
    Sponsor Name:Hermo Pharma Ltd
    Full Title: A Phase II, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of 10 Weeks Treatment with Fluoxetine 20 mg and Computer Software-Based Training in Adult Patients with Amblyopia
    Medical condition: treatment of adult amblyopia - amblyopia due to myopic or hyperopic anisometropia, or, congenital esotropia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10065008 Amblyopia unilateral LLT
    14.1 10015919 - Eye disorders 10015475 Esotropia LLT
    14.1 10015919 - Eye disorders 10042158 Strabismic amblyopia LLT
    14.1 10015919 - Eye disorders 10001906 Amblyopia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004409-42 Sponsor Protocol Number: LRP/LUBT010/2016/008 Start Date*: 2020-11-23
    Sponsor Name:Lupin Limited (Biotechnology Division)
    Full Title: A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Neovascular Age Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-005694-31 Sponsor Protocol Number: 2012/ADE002 Start Date*: 2013-07-05
    Sponsor Name:Adenovir Pharma AB
    Full Title: Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Mult...
    Medical condition: Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKC
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10014975 Epidemic keratoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002238-35 Sponsor Protocol Number: 11002X-001 Start Date*: 2012-10-04
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of an Investigational Eye Drop Formulation with OPTIVE™ Unit-Dose for 3 Months in Subjects with Dry Eye Disease
    Medical condition: Dry Eye Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10013774 Dry eye PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002931-32 Sponsor Protocol Number: APL2-GA-305 Start Date*: 2021-09-17
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004271-12 Sponsor Protocol Number: NGF0213 Start Date*: 2014-01-17
    Sponsor Name:Dompé s.p.a
    Full Title: An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye
    Medical condition: Dry Eye syndrome is caused by either decreased tear production or increased tear film evaporation. Dry eye is a chronic inflammatory condition of the ocular surface with severe symptoms and visual ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10013777 Dry eye syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005160-18 Sponsor Protocol Number: RP101-200 Start Date*: 2018-12-18
    Sponsor Name:Redwood Pharma AB
    Full Title: A Phase II, multicentre, randomised, placebo-controlled, double-masked trial of RP101 ophthalmic formulation versus vehicle in post-menopausal women with moderate to severe dry eye syndrome
    Medical condition: moderate or severe dry eye syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10013774 Dry eye PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003652-36 Sponsor Protocol Number: OZR-2011-17 Start Date*: 2012-11-30
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: The Most Effective Treatment Strategy for Diabetic Macular Edema.
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    15.0 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005556-25 Sponsor Protocol Number: OFT-ETAMSILATO-4.2.2 Start Date*: 2015-05-11
    Sponsor Name:Investigacion Independiente
    Full Title: Open extension study for patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulatedcontrolled treatment to evaluate safety and efficacy o...
    Medical condition: Aged related macula degeneration (ARMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001198-22 Sponsor Protocol Number: ALXN2040-GA-201 Start Date*: 2021-12-02
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
    Medical condition: Geographic Atrophy (AD) secondary to Age-related Macular Degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000590-93 Sponsor Protocol Number: CR213-20 Start Date*: 2023-06-09
    Sponsor Name:CuraTeQ Biologics Private Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (N...
    Medical condition: Wet (Neovascular) Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002698-20 Sponsor Protocol Number: OPT-302-1002 Start Date*: 2018-02-07
    Sponsor Name:Opthea Ltd
    Full Title: A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)
    Medical condition: Neovascular age-related macular degeneration (wet AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008259-41 Sponsor Protocol Number: OZR-2008-20 Start Date*: 2009-03-30
    Sponsor Name:Rotterdam Eye Hospital
    Full Title: Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) ...
    Medical condition: Age related macular degeneration and either of the following conditions: 1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003229-17 Sponsor Protocol Number: Protocol1 Start Date*: 2014-10-06
    Sponsor Name:Inst of OPhthalmology, Lund University
    Full Title: To compare the effect of Eylea given every other month after three injections to treatment with a gradual extension intervals. and examine retinal function with electroretinography (ERG) in patient...
    Medical condition: To evaluate if Aflibercept given every eighth week from start after an initial loading dose in age-related macular degeneration (AMD), is as effective as dosing as "Treat and extend" where treati...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002524-12 Sponsor Protocol Number: BNZ-20-01-2022 Start Date*: 2023-04-13
    Sponsor Name:AZAD Pharma AG
    Full Title: A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Br...
    Medical condition: GLAUCOMA , OCCULAR HYPERTENSION
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005417-38 Sponsor Protocol Number: CRFB002G2301 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) LV (Completed) PT (Completed) HU (Completed) CZ (Completed) ES (Completed) LT (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000921-39 Sponsor Protocol Number: PH-BRINLOL-01 Start Date*: 2019-04-24
    Sponsor Name:PHARMATHEN SA
    Full Title: A prospective, phase III, multicenter, randomized, investigator-masked, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety and of a generic fixed combination ...
    Medical condition: open-angle glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) CY (Completed)
    Trial results: View results
    EudraCT Number: 2011-002350-31 Sponsor Protocol Number: CRFB002E2401 Start Date*: 2012-02-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab in...
    Medical condition: visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10025415 Macular oedema PT
    14.1 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed) GR (Completed) PT (Completed) NL (Completed) PL (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003653-16 Sponsor Protocol Number: S62092 Start Date*: 2019-03-21
    Sponsor Name:UZ Leuven
    Full Title: Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study
    Medical condition: Birdshot Uveitis HLA A29 retinochoroiditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10072959 Birdshot chorioretinopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002977-33 Sponsor Protocol Number: Luc01AKSI Start Date*: 2006-06-22
    Sponsor Name:University Eye Hospital
    Full Title: Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to ag...
    Medical condition: Age related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years in the developed world. Eighty to ninety percent of rapid and severe vision loss due to A...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 19:49:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA